News of Note—FDA gets specific on data integrity rules; Lupin, Dishman tagged with 483s


Here is some news of note for the week:

> The FDA has posted information about its now-completed "Data Integrity and Compliance With Drug CGMP" guidance. Q&A

> CDMO Cambrex will invest $1 million at its High Point, North Carolina, site to fit out a 1,300-square-foot analytical laboratory space. Release

> India’s Lupin has downplayed the 22 observations it got in an FDA inspection of its Mandideep cardiovascular “Pril” facility, its cephalosporin API facility and cephalosporin solid oral facility. Release

> India’s Dishman has received a Form 483 in which it got two observations for a plant in Gujarat including one in which it was found to be blending batches that were out of spec for an impurity with batches that met specs. 483

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.